GlassVC

Roche Venture Fund

Venture capital firm · Founded 2002 · Basel, Switzerland

Roche Venture Fund is the corporate venture capital arm of Roche, investing the group's balance-sheet capital in pharmaceutical, diagnostics and digital health companies aligned with Roche's strategy.

Tier 4Basis: T3: the firm's own page states a CHF 750M evergreen fund, above the $250M fund threshold in substance; no USD AUM or discrete vintage fund is recorded because the figure is CHF-denominated.

Tier reflects published scale and track-record signals. It is not a rating of the firm as a partner.

This profile is unclaimed. Built from public sources. If you're a partner or employee at Roche Venture Fund, you can claim it.

Claim this profileHow claiming works

Key numbers

Assets under management

Not publicly disclosed

LAST CHECKED NOV 2026

Latest fund

Not publicly disclosed

LAST CHECKED NOV 2026

Funds

No public record

LAST CHECKED NOV 2026

Check size

Not publicly disclosed

LAST CHECKED NOV 2026

Stages

No public record

Sectors

PharmaceuticalsDiagnosticsDigital health

FIGURES ARE AS PUBLISHED IN THE CATALOG RECORD 1 · PER-FIGURE AS-OF DATES ARE NOT YET IN THE CATALOG

Track record

Outcomes are recorded from public sources and attributed to the firm, not to individual partners. Shutdowns and write-offs are an ordinary part of venture investing; inclusion here is a record, not a judgment.

Hits

  • AveXis

    Roche Venture Fund portfolio exit cited in Mergermarket/Ion coverage: acquired by Novartis for USD 8.7 billion

  • Pandion Therapeutics

    Roche Venture Fund portfolio exit cited in Mergermarket/Ion coverage: acquired by Merck for USD 1.85 billion

  • Good Therapeutics

    Acquired by Roche in 2022 for USD 250 million in cash plus milestones (per Ion/Mergermarket coverage of RVF)

Misses

Track record

No outcomes recorded yet from public sources.

Partners

Partners

No partners listed from public sources.

Reputation

No reputation score — basis not established for this firm.

No reputation sources on file yet.

Suggest a source

Contact

Published sources only

Published contact

Published sources only

GlassVC lists only contact information the firm or its sources have published. We do not list personal emails, direct lines, or private addresses.

SOURCE: FIRM WEBSITE, AS PUBLISHED 2

What founders say

Founder-submitted · Verified identity and relationship

No founder reviews yet

Be the first founder to share your experience with Roche Venture Fund. Reviews come from founders whose identity and relationship have been verified.

Write the first review

Methodology

Tier basis — T3: the firm's own page states a CHF 750M evergreen fund, above the $250M fund threshold in substance; no USD AUM or discrete vintage fund is recorded because the figure is CHF-denominated. Tier reflects published scale and track-record signals. It is not a rating of the firm as a partner.

Figures are shown as published; conflicting figures are never averaged. Review dimension scores appear only once three founders have reviewed this firm; profiles below that threshold do not appear in rated lists.

The catalog does not yet carry per-figure citations or as-of dates: every figure on this page traces to the catalog record listed below, and that limit is stated rather than papered over. Corrections with a source: Suggest a correction.

Source record 2

  1. [1]

    DATABASE · GlassVC catalog — Catalog record for Roche Venture Fund — provenance: GlassVC editorial — entered manually

    CATALOG SOURCE FIELD · LAST CHECKED NOV 2026

    ↩ cites: AUM · Check size · Founded · HQ · Stages · Sectors · Track record

  2. [2]

    FIRM SITE · Roche Venture Fund — Firm website, as published by the firm

    LAST CHECKED NOV 2026 ↗

    ↩ cites: Website

PROFILE BUILT FROM PUBLIC SOURCES · 2 CATALOG SOURCES · LAST CHECKED NOV 2026